行情

REGN

REGN

再生元制药
NASDAQ

实时行情|Nasdaq Last Sale

449.52
-2.78
-0.61%
盘后: 454.99 +5.47 +1.22% 19:58 03/27 EDT
开盘
446.03
昨收
452.30
最高
465.79
最低
445.15
成交量
110.92万
成交额
--
52周最高
518.00
52周最低
271.37
市值
494.56亿
市盈率(TTM)
24.34
分时
5日
1月
3月
1年
5年

分析师评级

26位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测REGN价格均价为474.96,最高价位600.00,最低价为370.00。

EPS

REGN 新闻

更多
  • Sanofi, Regeneron expand testing of potential coronavirus treatment
  • Reuters · 43分钟前
  • First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19
  • PR Newswire · 1小时前
  • Ex-FDA Chief Gottlieb Expects Coronavirus Therapeutic Option By Summer
  • Benzinga · 8小时前
  • 2 Biotech Giants in the Hunt for New Coronavirus Drugs
  • TipRanks · 18小时前

所属板块

生物技术和医学研究
-2.44%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

REGN 简况

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.
展开

微牛提供Regeneron Pharmaceuticals Inc(NASDAQ-REGN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的REGN股票新闻,以帮助您做出投资决策。